Compare · DXCM vs PRCT
DXCM vs PRCT
Side-by-side comparison of DexCom Inc. (DXCM) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 31.8x PRCT ($1.04B).
- Over the past year, DXCM is up 29.2% and PRCT is down 46.8% - DXCM leads by 76.0 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- PROCEPT BioRobotics Corporation
- Price
- $86.05-1.93%
- $17.57-3.17%
- Market cap
- $33.10B
- $1.04B
- 1M return
- -2.13%
- -9.76%
- 1Y return
- +29.24%
- -46.76%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest PRCT
- PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026
- Barclays initiated coverage on PROCEPT BioRobotics with a new price target
- SEC Form 4 filed by PROCEPT BioRobotics Corporation
- SEC Form 3 filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- EVP, CLO, CORP. SEC. Nouri Alaleh sold $6,223 worth of shares (297 units at $20.95), decreasing direct ownership by 0.23% to 127,737 units (SEC Form 4) to cover withholding tax
- EVP, Chief Technology Officer Templin Barry L sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.39% to 94,826 units (SEC Form 4) to cover withholding tax
- EVP, CFO Waters Kevin sold $7,815 worth of shares (373 units at $20.95), decreasing direct ownership by 0.21% to 180,355 units (SEC Form 4) to satisfy withholding tax
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026